CRISPR Therapeutics AG (CRSP) Stock

Healthcare · Biotechnology · Member of Other US Stocks

CRISPR Therapeutics AG (CRSP) closed at USD 50.22 on 2026-10-14, a change of -21.7 % over the past year, with a market capitalization of USD 4.98B.

CRISPR Therapeutics AG recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

CRISPR Therapeutics AG key figures

Previous close

USD 50.22 (2026-10-14)

1-year change

-21.7 %

Market cap

USD 4.98B

Enterprise value

USD 3.4B

P/E ratio (trailing)

-10.58

P/E ratio (forward)

-14.50

EPS (trailing)

-4.87

EPS (forward)

-3.55

PEG ratio

n/a

Price to book

2.85

Revenue growth

1,041.4 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

11.76

Employees

n/a

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About CRISPR Therapeutics AG

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for CRISPR Therapeutics AG and compare it with other stocks.